• Enliven Therapeutics Chief Medical Officer Helen Louise Collins exercised stock options for 5,000 shares at $2.48 on Aug. 17, 2026.
• She sold 5,000 shares the same day in two transactions at weighted average prices of $58.37 and $59.35.
• Directly held common stock position stood at 25,000 shares following the transactions.
• Directly held stock options totaled 111,268 following the exercise.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001701247-26-000012), on August 19, 2026, and is solely responsible for the information contained therein.